Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Given Consensus Rating of “Buy” by Analysts

Shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) have received a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $16.75.

A number of research firms have weighed in on MRNS. Cantor Fitzgerald reiterated a “buy” rating and issued a $60.00 target price on shares of Benefitfocus in a research note on Wednesday, May 1st. ValuEngine lowered shares of China Southern Airlines from a “hold” rating to a “sell” rating in a research report on Monday, April 29th. LADENBURG THALM/SH SH raised shares of Energous from a “neutral” rating to a “buy” rating and set a $6.50 price target on the stock in a research report on Wednesday, May 1st. Finally, Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd.

Marinus Pharmaceuticals stock traded up $0.01 during midday trading on Friday, hitting $4.58. 307,196 shares of the stock were exchanged, compared to its average volume of 451,777. Marinus Pharmaceuticals has a 52-week low of $2.36 and a 52-week high of $10.54. The company has a market capitalization of $240.70 million, a PE ratio of -5.09 and a beta of 2.94. The stock’s 50-day simple moving average is $4.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.03). On average, equities analysts predict that Marinus Pharmaceuticals will post -0.86 EPS for the current fiscal year.

In related news, CFO Edward F. Smith sold 24,211 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $5.03, for a total transaction of $121,781.33. Following the sale, the chief financial officer now owns 20,097 shares of the company’s stock, valued at approximately $101,087.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. 683 Capital Management LLC increased its holdings in shares of Marinus Pharmaceuticals by 22.7% in the 4th quarter. 683 Capital Management LLC now owns 1,350,000 shares of the biopharmaceutical company’s stock worth $3,875,000 after buying an additional 250,000 shares during the last quarter. Tekla Capital Management LLC increased its holdings in shares of Marinus Pharmaceuticals by 124.8% in the 4th quarter. Tekla Capital Management LLC now owns 755,776 shares of the biopharmaceutical company’s stock worth $2,169,000 after buying an additional 419,548 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Marinus Pharmaceuticals by 34.7% in the 4th quarter. Geode Capital Management LLC now owns 464,483 shares of the biopharmaceutical company’s stock worth $1,332,000 after buying an additional 119,668 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Marinus Pharmaceuticals by 76.4% in the 4th quarter. Millennium Management LLC now owns 315,842 shares of the biopharmaceutical company’s stock worth $906,000 after buying an additional 136,830 shares during the last quarter. Finally, Highbridge Capital Management LLC bought a new position in shares of Marinus Pharmaceuticals in the 4th quarter worth $762,000. 63.35% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Article: How can you know how many shares are floating?

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.